2024-07-26 12:34:32 ET
Summary
- Today, we take a look at NovoCure Limited, which develops and manufactures tumor treating fields devices for solid tumor cancers.
- The company has beat expectations for both its first and second quarter results in 2024 and is pushing to garner approval for additional indications.
- An analysis of NovoCure following its better than expected performance Q2 results Thursday follows in the paragraphs below.
Today, we put NovoCure Limited ( NVCR ) in the spotlight. The company reported better than expected quarterly earnings for the second time in 2024 on Thursday. The company has a somewhat unique way to treat various forms of cancer. The stock has risen some 25% so far in 2024. Can the rally continue? An analysis follows below. ...
Read the full article on Seeking Alpha
For further details see:
NovoCure Limited: A Post Q2 Analysis